Cheniere Energy Partners, L.P. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cheniere Energy Partners, L.P. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.76B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $9.66B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $17.21B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $9.43B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $2.00B | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $982.00M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $1.47B | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $1.72B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $1.91B | Feb 24, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.76B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $9.66B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $17.21B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $9.44B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $6.17B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $6.84B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.43B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $4.30B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.10B | Feb 26, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.51B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.25B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.50B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.63B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $409.00M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($67.00M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $406.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $435.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $448.00M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.28B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.04B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.38B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.56B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $625.00M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $152.00M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $684.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $664.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $676.00M | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.00M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $3.00M | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $9.32M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $11.32M | Feb 19, 2016 |
| FY2014 | Dec 31, 2012 | $37.56M | Feb 20, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.77B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.97B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.11B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.29B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.75B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.55B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.87B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $977.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $154.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $220.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $451.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $648.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $972.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.33B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $804.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.29B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $2.32B | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.44B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.45B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.10B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $19.63B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $19.36B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $19.15B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $19.38B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $17.97B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $17.55B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $15.54B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.96B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.89B | Feb 20, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $270.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $575.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $904.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $876.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.21B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.78B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.16B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.76B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.61B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $16.20B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $17.18B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $17.58B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $17.58B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $16.07B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $16.05B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $14.21B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Sep 30, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Mar 31, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Feb 24, 2017 |
| FY2011 | Dec 31, 2011 | 1 | Feb 24, 2012 |
| FY2011 | Dec 31, 2010 | 1 | Feb 24, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Sep 30, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Mar 31, 2016 | 0 | Feb 24, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Feb 24, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Feb 24, 2017 |